In melanoma, glioma, ovarian cancer, and some other cancers, the overexpression of BRD2 and BRD4 is associated with poor prognosis, and their presence affects the pathways of nuclear factor-κB (NF-κB), Notch, and Hedgehog (Hh) signaling (4–6). Here, BRD2 is linked to ovarian cancer.